HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.

AuthorsIria Castiñeiras, Luisa Fernández-Diaz, Yolanda Juárez, Mercedes Lueiro
JournalThe Journal of dermatology (J Dermatol) Vol. 39 Issue 8 Pg. 730-1 (Aug 2012) ISSN: 1346-8138 [Electronic] England
PMID22364316 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Ustekinumab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Dermatitis, Exfoliative (drug therapy)
  • Dermatologic Agents (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Psoriasis (drug therapy)
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Ustekinumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: